Phytanix Bio, SPAC Company Chain Bridge I Enter Definitive Business Combination Agreement; Combined Company To Be Named Phytanix Inc.
Phytanix Bio, SPAC Company Chain Bridge I Enter Definitive Business Combination Agreement; Combined Company To Be Named Phytanix Inc.
Phytanix Bio、SPAC公司Chain Bridge I簽署最終業務合併協議；合併後的公司將命名爲Phytanix Inc。
Upon closing of the transaction, expected to occur in the fourth quarter of 2024, the combined company will be named Phytanix Inc., and its common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol "PHYX."
預計將於2024年第四季度進行的交易完成後，合併後的公司將被命名爲Phytanix Inc.，其普通股預計將在納斯達克資本市場上市，股票代碼爲 “PHYX”。
Phytanix is pioneering a new and innovative approach in the development of cannabinoid and cannabinoid-like medicines.
Phytanix在開發大麻素和類大麻素藥物方面開創了一種新的創新方法。
The transaction reflects a pre-deal valuation of $58 million for Phytanix Bio plus the assumption of $17 million of preferred stock and $4.4 million of short-term debt that will be exchanged for convertible preferred stock at deal close
該交易反映了Phytanix Bio的交易前估值爲5800萬美元，外加假設的1700萬美元優先股和440萬美元的短期債務，這些債務將在交易結束時兌換成可轉換優先股